149 results about "Interleukin 10" patented technology

Interleukin-10 (IL-10) conjugated via a linker to one or more polyethylene glycol (PEG) molecules at a single amino acid residue of the IL-10, and a method for preparing the same, are provided. The method produces a stable mono-pegylated IL-10, which retains IL-10 activity, where pegylation is selective for the N-terminus on one subunit of IL-10 with little or no formation of monomeric IL-10. The method also provides a substantially homogenous population of mono-PEG-IL-10.

The methods and compositions provided herein relate generally to IL-10 specific antibodies and uses thereof. More specifically, compositions of humanized IL-10 specific antibodies and methods to use such antibodies in modulating the biological activity of IL-10, particularly in autoimmune disorders and pathogen-mediated immunopathology.

The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1 mediated diseases, including inflammatory diseases, autoimmune diseases and neurodegenerative diseases. This invention also relates to methods for inhibiting ICE activity and methods for treating interleukin-1 mediated diseases using the compounds and compositions of this invention.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Cytoplasmic aspartate aminotransferase, soluble Tumor necrosis factor receptor superfamily member 5, soluble CD40 Ligand, soluble C-X-C Motif chemokine 16, S100-A12, Eotaxin, soluble E-selectin, Fibronectin, Granulocyte colony-stimulating factor, Granulocyte-macrophage colony-stimulating factor, Heparin-binding growth factor 2, soluble Hepatocyte growth factor receptor, Interleukin-1 receptor antagonist, Interleukin-1 beta, Interleukin-10, Interleukin-15, Interleukin-3, Myeloperoxidase, Nidogen-1, soluble Oxidized low-density lipoprotein receptor 1, Pappalysin-1, soluble P-selectin glycoprotein ligand 1, Antileukoproteinase, soluble Kit ligand, Tissue inhibitor of metalloproteinase 1, Tissue inhibitor of metalloproteinase 2, soluble Tumor necrosis factor, soluble Vascular cell adhesion molecule 1, and Vascular endothelial growth factor A as diagnostic and prognostic biomarkers in renal injuries.

Polypeptides comprising at least a first and second Fc fragment of IgG that can be used to induce a stimulated cell to produce the anti-inflammatory cytokine Interleukin-10 and methods of using the same are disclosed herein.

A mathematical prognostic in which changes in a number of physiologically significant factors are measured and interpolated to determine a "damage function" incident to bacterial infection or other serious inflammation. By measuring a large number of physiologically significant factors including, but not limited to, Interleukin 6 (IL6), Interleukin 10 (IL10), Nitric Oxide (NO), and others, it is possible to predict life versus death by the damage function, dD / dt, which measures and interpolates differential data for a plurality of factors. In mammals, an IL6 / NO ratio <8 at 12 hours post infection is highly predictive (60%) of mortality; also in mammals, an IL6 / NO ratio <4 at 24 hours post infection is highly predictive (52%) of mortality; and an IL6 / IL10 ratio in mammals of <7.5 at 24 hours post infection is highly predictive (68%) of mortality.

The methods and compositions provided herein relate generally to IL-10 specific antibodies and uses thereof. More specifically, the methods and compositions provided herein relate to humanized IL-10 specific antibodies and methods to use such antibodies in modulating the biological activity of IL-10, particularly in autoimmune disorders and pathogen-mediated immunopathology.

The present invention describes using, on a repetitive basis, a non-human colonizing helminth compound, in an amount sufficient to establish a transitory parasitic helminth infection and or to simulate in a parasitic helminth infection, thereby having immunosuppressive effect against benign antigens and or stimulating a regulatory immune response characterized by the production of T helper cells 2 (Th2), T regulatory helper cells (TREG) and certain cytokines, including, but not limited to interleukin 10 (IL-10), as a therapy or prophylaxis of allergy and other IgE-mediated disorders, which are marked by an inappropriate IgE immune response including, but not limited to an aberrant and or enhanced IgE antibody production to benign antigens. The invention presents using helminth compound by administering it in a frequency and amount sufficient to eliminate or ameliorate the inappropriate immune response in an asthmatic and or allergic individual.

An adoptive immunotherapy using ex vivo-generated regulatory T cells may be used for the suppression of undesireable immune response. T cells are to be obtained from the patient's blood, and upon exposure to a set of toxins from the pathogen A. actinomycetemcomitans, the population of regulatory T cells will be enriched ex vivo and adoptively transferred back to the patient. The novel aspect of the present invention is that it generates large numbers of type 1 regulatory T cells, which secrete Interleukin-10.

The present invention generally relates to fusion proteins of antibodies and interleukin-10 (IL-10). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.

This invention relates to interleukin-10 (IL-10) polypeptide conjugates comprising at least one non-naturally-encoded amino acid.

The present invention relates to a purified nucleic acid sequence encoding a homologue of human interleukin 10 (IL-10), wherein said IL-10 homologue is expressed during the latent phase of infection by a virus of the herpesvirideae group. The present invention also relates to uses of this polypeptide, in particular for diagnosing disease states and screening for modulator and inhibitor compounds of such polypeptides and in turn the virus itself, screening for infection in vertebrates and biological tissue, cleansing of infected biological tissues, and in the treatment and / or prophylaxis and / or diagnosis of disease caused by a virus of the herpesvirideae group.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Cytoplasmic aspartate aminotransferase, soluble Tumor necrosis factor receptor superfamily member 5, soluble CD40 Ligand, soluble C-X-C Motif chemokine 16, S100-A12, Eotaxin, soluble E-selectin, Fibronectin, Granulocyte colony-stimulating factor, Granulocyte-macrophage colony-stimulating factor, Heparin-binding growth factor 2, soluble Hepatocyte growth factor receptor, Interleukin-1 receptor antagonist, Interleukin-1 beta, Interleukin-10, Interleukin-15, Interleukin-3, Myeloperoxidase, Nidogen-1, soluble Oxidized low-density lipoprotein receptor 1, Pappalysin-1, soluble P-selectin glycoprotein ligand 1, Antileukoproteinase, soluble Kit ligand, Tissue inhibitor of metalloproteinase 1, Tissue inhibitor of metalloproteinase 2, soluble Tumor necrosis factor, soluble Vascular cell adhesion molecule 1, and Vascular endothelial growth factor A as diagnostic and prognostic biomarkers in renal injuries.

Methods of treating subjects having a disease or disorder responsive to IL-10, including methods of administration and dosing regimens associated therewith, are provided.

The invention discloses a fusion protein with transdermal capability and interleukin 10 activity as well as a coding gene and application thereof. The fusion protein provided by the invention is formed by connecting any one protein of (1) human IgG Fc-gamma1 or the mutain thereof and (2) human IgG Fc-gamma2 or the mutain thereof on the carboxyl terminal of a human interleukin 10 protein, and connecting a transit peptide on an amino terminal; wherein the amino acid sequence of the human interleukin 10 protein is the amino acid sequence from the 12th site to the 171st site on the amino terminal of a sequence 2 in a sequence table; and the amino acid sequence of the transit peptide is the amino acid sequence from the 1st site to the 11th site on the amino terminal of the sequence 2 in the sequence table. Tests prove that the fusion protein provided in the invention has the transdermal capability and the interleukin 10 activity simultaneously, and has greater practical significance and broad application prospect in the field of the preparation of medicaments for treating autoimmunity reaction and especially psoriasis.

This invention is related to the use of at least one oligonucleotide with a length of from about 8 to about 30 nucleotide building blocks for manufacturing a pharmaceutical preparation for the prophylaxis and / or the treatment of diseases, that are modulated by TGF-beta2, TGF-beta1, TGF-beta3, VEGF, interleukin-10, c-jun, c-fos, and / or prostaglandin E2 in a mammal, wherein said oligonucleotide hybridizes with a messenger RNA of a TGF-beta2, TGF-beta1, TGF-beta3, VEGF, interleukin-10, c-jun, c-fos and / or prostaglandin E2 gene and wherein said preparation comprises said oligonucleotide in a concentration of about 1 microM to about 25 microM.

Polypeptides comprising at least a first and second Fc fragment of IgG that can be used to induce a stimulated cell to produce the anti-inflammatory cytokine Interleukin-10 and methods of using the same are disclosed herein.

The invention discloses a fusion protein and a coding gene and application thereof. The fusion protein provided by the invention is formed by connecting any one of the following proteins at the carboxyl terminal of human interleukin-10 protein: 1) human IgGFc-gamma 1 or mutant protein thereof, and 2) human IgGFc-gamma 2 or mutant protein thereof, wherein the amino acid sequence of the human interleukin-10 protein is an amino acid sequence from 1st to 160th site of the amino terminal of the sequence 1 in a sequence table. Proved by experiments, the IL-10-IgG / Fc fusion protein of interleukin-10activity is produced by using a pichia pastoris fermentation expression system, and a foundation for clinically researching the treatment effect of the IL-10-IgG / Fc fusion protein in the next step.

A method for treating renal disease includes administering to a patient suffering from renal disease an effective amount of antibody or of a functional equivalent thereof to at least two of urea, creatinine, tumor necrosis factor alpha, interferon gamma, interleukin 6 and interleukin 1 beta. Soluble cytokine receptors also can be employed. Antibody, functional equivalent thereof or soluble cytokine receptor to interleukin 10 or interleukin 13 also can be administered. The method can be used as a supplement to or as partial or complete replacement for dialysis. A pharmaceutical composition includes antibody or functional equivalent thereof to urea, creatinine, or both; antibody, functional equivalent or soluble cytokine receptor to tumor necrosis factor alpha, interferon gamma, interleukin 6, interleukin 1 beta or any combination thereof; and, optionally, antibody, functional equivalent or soluble cytokine receptor to interleukin 10, interleukin 13 or both. The composition can be included in a kit.

The present disclosure is directed to interleukin-10 (IL-10) peptides and isolated antibodies that specifically bind to the IL-10 peptides. The IL-10 peptides and the isolated antibodies may be administered alone or as an animal feed additive to treat gastrointestinal protozoan infection in animals.

The invention relates to the field of genetic engineering medicines, in particular to a human interleukin 10-Fc (IL10-Fc) fusion protein, and a coding gene and application thereof. By replacing aminoacids at multiple positions in an IgG4Fc part, the modified IL10-Fc fusion protein has superior performance over existing Fc fusion proteins, such as increasement of in-vivo stability, elimination ofunnecessary effector functions and reduction of immunogenicity of the fusion proteins in living organisms. The invention also discloses a method for treating diseases by using an IL10-Fc fusion protein medicament, and the method comprises administering a therapeutically effective amount of the medicament to a subject suffering from diseases, wherein the diseases comprise an inflammatory symptom, immune related diseases, fibrosis diseases, cancers and the like.

The present invention provides compositions and methods for upregulating IL-10 production in a stimulated cell. In one aspect, the invention provides methods of identifying ERK activating agents capable of activating and amplifying the ERK MAPK pathway in a cell. Such ERK activating agents are capable of upregulating the production of IL-10 in stimulated cells. In another aspect, the invention provides ERK activating agents identified by the screening methods of the invention. Methods are also provided for preventing and treating inflammation in a susceptible patient by administering to the patient, a therapeutically effective amount of an ERK activating agent identified in accordance with the invention.

It has been discovered that reducing, inhibiting or preventing the expression of immunosuppressive cytokines or tolergenic agents in antigen presenting cells improves the ability of the antigen presenting cell to promote an immune response. One embodiment provides a genetically engineered antigen presenting cell that has reduced or no expression of IL-10. Preferred antigen presenting cells are dendritic cells. Expression of IL-10 can be inhibited or blocked by genetically engineering the antigen presenting cell to express inhibitory nucleic acids that inhibit or prevent the expression mRNA encoding immunosuppressive cytokines. Inhibitory nucleic acids include siRNA, antisense RNA, antisense DNA, microRNA, and enzymatic nucleic acids that target mRNA encoding immunosuppressive cytokines. Immunosuppressive cytokines include, but are not limited to IL-10, TGF-β, IL-27, IL-35, or combinations thereof. Tolerogenic agents include but are not limited to indoleamine 2,3-dioxygenase.

The present invention generally relates to fusion proteins of antibodies and interleukin-10 (IL-0). More particularly, the invention concerns fusion proteins of antibodies and mutant IL-10 that exhibit improved properties for use as therapeutic agents, e.g. in the treatment of inflammatory diseases. In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the fusion proteins of the invention, and to methods of using them in the treatment of disease.

Described herein are methods of reducing Salmonella in the intestines of poultry in need thereof by administering to a poultry bird an effective amount of an interleukin-10 peptide or an isolated antibody that specifically binds an interleukin-10 peptide. Administering may be performed within 1 to 4 weeks of harvest of the poultry in order to reduce Salmonella transmission to human consumers. Also included herein are finishing feeds that include an interleukin-10 peptide or an isolated antibody that specifically binds an interleukin-10 peptide.

The invention discloses a liquid band-aid, comprising, active materials, a film-forming material and a solvent. The active materials include cytokines 0.042 to 0.0095%, which are chosen from at least two of EGF (epidermal growth factor), PDGF (platelet derived growth factor), FGF (fibroblast growth factor) and IL-10 (interleukin-10). The film-forming material comprises chitosan hydrochloride 2% to 8%. The solvent is deionized water or distilled water. The invention further discloses a method for preparing the liquid band-aid. By the use of the preparation method and / or the liquid band-aid comprising various biological active materials and prepared by the preparation method, activity of the biological active materials can be retained, and wounds can be efficiently repaired without a scar.

The present disclosure is directed to interleukin-10 (IL-10) peptides and isolated antibodies that specifically bind to the IL-10 peptides. The IL-10 peptides and the isolated antibodies may be administered alone or as an animal feed additive to treat gastrointestinal protozoan infection in animals.

A peptide or peptidomimetic comprising an amino acid sequence based on conserved regions of IL10 or IFN-gamma receptor sequences, and related compounds and compositions, as well as methods for the use thereof to inhibit cytokine signaling.

The invention provides application of nitidine chloride to the preparation of a medicament for resisting autoimmunity disease and graft versus host disease. An experiment shows that the nitidine chloride can inhibit the proliferation of human dendritic cells in vitro, inhibit the human dendritic cells from promoting the proliferation reaction of allogeneic T cells and strengthen the capacity of secreting interleukin 10 of the human dendritic cells. Meanwhile, in an experimental autoimmunity disease cerebrospinal meningitis model, when used in vivo, the nitidine chloride can reduce the average clinical score of a mouse and inhibit the spinal marrow infiltration degree of monocytes and can obviously improve the secretion level of the interleukin 10 in the blood serum of the mouse. In a heart transplantation experiment, when used in vivo, the nitidine chloride can prolong the survival time of the transplanted heart. In a delayed type hypersensitivity reaction model, when used in vivo, the nitidine chloride can reduce the ear swelling degree of the mouse. Both in-vivo and in-vitro results show that the nitidine chloride has a certain effect of resisting the autoimmunity disease and the graft versus host disease. The medicament is a preparation which consists of the nitidine chloride serving as an active ingredient and a pharmaceutical carrier. The medicament can be prepared into an oral preparation, an injection, a suppository or an external preparation and the like.